AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03751566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard supportive therapy
Description: Standard supportive therapy
Study NCT03639467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus gemcitabine/cisplatin
Description: In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first.
Study NCT02534298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: functional magnetic resonance imaging
Description: functional magnetic resonance imaging
Study NCT02534298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: functional magnetic resonance imaging
Study NCT03096704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vitamine d dosage
Description: dosage of vitamine D in slow transit time constipation
Study NCT03505541 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adiponectin and TNFa
Description: Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility
Study NCT01103362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: all patients will receive open-label flibanserin 100mg
Study NCT02033161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment.
Study NCT01048671 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.
Study NCT01048671 — intervention group
Intervention type: DRUG
Intervention: ARV (non-raltegravir)
Description: ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
Study NCT04619901 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Exploring the psychological and social impact on parents of a palliative care decision concerning their child in the neonatal period
Study NCT04619901 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents
Study NCT04619901 — intervention group
Intervention type: OTHER
Intervention: following Scales
Description: Scales : Hospital Anxiety and Depression, Intolerance to Uncertainty, and Brief COPE.
Study NCT04114630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erenumab 70mg/mL
Description: Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors
Study NCT02567500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients with auditory hallucination
Description: Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS
Study NCT02567500 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Patients without auditory hallucination
Description: Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS
Study NCT04080921 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study NCT03481192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Two visits for evaluation
Description: Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition.
Study NCT03481192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two visits for evaluation
Description: Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition.
Study NCT02536807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronan
Description: HA gel injection
Study NCT02536807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronan
Description: HA gel injection
Study NCT03060668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptamen intense
Description: Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
Study NCT03060668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novasource senior
Description: Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
Study NCT02277002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cabin Air Filtration
Study NCT02277002 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Cabin Air Filtration
Study NCT02901782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized titanium plate
Description: 3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
Study NCT03009760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg(HP-)
Description: CJ-12420 50mg in H. pylori negative subject
Study NCT03009760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg(HP-)
Description: CJ-12420 100mg in H. pylori negative subject
Study NCT03009760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg(HP+)
Description: CJ-12420 50mg in H. pylori positive subject
Study NCT03009760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg(HP+)
Description: CJ-12420 100mg in H. pylori positive subject
Study NCT03715439 — intervention group
Intervention type: DEVICE
Intervention: Dental implant
Description: A single dental implant was inserted 3 months after tooth extraction
Study NCT03587077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: vaginal application
Study NCT03587077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: vaginal application
Study NCT03587077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: vaginal application
Study NCT03587077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosorbide mononitrate
Description: vaginal application
Study NCT01097382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOLPIDEM
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
Study NCT00617474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
Study NCT00617474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00407277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 21 mg of nicotine via a dermal patch
Study NCT00407277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo via a dermal patch
Study NCT00407277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation group therapy
Description: a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders
Study NCT04612374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Please see arm/group descriptions
Study NCT04612374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Please see arm/group descriptions
Study NCT02810548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD alone
Description: Periodontal surgical cleaning procedure
Study NCT02810548 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: OFD alone
Description: Periodontal surgical cleaning procedure
Study NCT02810548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich Fibrin
Description: Natural platelet concentrate rich in growth factors
Study NCT02810548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanohydroxyapatite
Description: Synthetic bone graft
Study NCT01303731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Fentanyl
Description: Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
Study NCT01303731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
Study NCT03676231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-1019
Description: Active
Study NCT03676231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive
Study NCT00857272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG electrolyte lavage solution + bisacodyl - reformulation
Description: multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
Study NCT00857272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG electrolyte lavage solution + bisacodyl
Description: multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
Study NCT02504944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol 0.2% eye drops
Description: Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
Study NCT03058146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Walking Condition
Description: Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
Study NCT03058146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Education Condition
Description: The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
Study NCT01706133 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Factors associated with the use of emergency departments
Description: Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
Study NCT02293694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
Study NCT00728585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV
Study NCT00728585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT01275131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Study NCT01275131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study NCT03265938 — intervention group
Intervention type: DEVICE
Intervention: Indirect Laryngoscopy
Description: The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
Study NCT04112121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meeting with a Chaplain coupled with Biblical Readings
Study NCT03378505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: Purposeful Living Mobile App JOOL to be used daily
Study NCT03378505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection
Description: Bi-weekly online reflection question
Study NCT02292654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olipudase alfa
Description: Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
Study NCT01924520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral
Study NCT03871842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.
Study NCT03871842 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.
Study NCT00978653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: 150 mg once a day
Study NCT03945825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AF03
Description: A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether
Study NCT03945825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delta Inulin-CpG55.2
Description: A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)
Study NCT03945825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: 2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
Study NCT03945825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: 2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
Study NCT00690118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 45 mg/day, 18 months
Study NCT00690118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily, 18 months
Study NCT00573495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT/Survivin Multi-Peptide Vaccine
Description: 100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
Study NCT01090622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Oral capsule
Study NCT01090622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT00550875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen allergenic extract (L. perenne-C. dactylon )
Description: Sublingual. 2 drops/daily 1000 DPP/ml 2 years
Study NCT00550875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen allergenic extract (L. perenne-C. dactylon )
Description: Sublingual. 2 drops/daily 10000 DPP/ml 2 years
Study NCT00550875 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sublingual. 2 drops/daily 2 years
Study NCT02949466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
Study NCT02949466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
Study NCT02949466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis